title: ERCC1 plays an important role in predicting survival outcomes and treatment response for patients with HNSCC: a meta-analysis.
abstract: BACKGROUND
  Excision repair crosscomplementing-1 (ERCC1) has been reported to play a prognostic role and may indicate the treatment response in patients with head and neck squamous carcinoma (HNSCC). Nevertheless, the strength of evidence of ERCC1 predicting these two clinical outcomes are still controversial.
  
  
  METHODS
  Potentially eligible studies were retrieved using PubMed, Embase and Medline. Basic clinical characteristics of patients and statistical data with the survival data were collected. Then a meta-analysis model was established to investigate the correlation between over-expression of ERCC1 and survival outcome in HNSCC patients as well as to determine whether the treatment response is dependent on expression stature of ERCC1 or not.
  
  
  RESULTS
  17 eligible studies and 1263 patients were yielded in our meta-analysis. The pooled HRs with 95% confidence intervals (CIs) for OS and PFS were 2.14 [1.51, 3.05] and 2.60 [1.98, 3.42], respectively. In terms of subgroup analysis, race was found to be a significant factor divided for these analyses, and the pooled HRs for the Asian subgroup are 2.97 [2.05, 4.32] and 2.75 [1.82, 4.13] respectively. In non-Asian subgroup, Pooled HRs indicate the predict role for PFS 2.42 [1.60, 3.66], but no value for OS (P<0.05). With regard to treatment response, the pooled ORs were 3.04 [1.99, 4.62]. Results from subgroup analysis that divided by race further showed that pooled ORs in Asian group were 3.95 [2.30, 6.78] and 1.93 [0.97, 3.84] in non-Asian group.
  
  
  CONCLUSIONS
  ERCC1 could be a fine prognostic factor of HNSCC and can also prompt the treatment response, which might be proven by further multicenter clinical trials.
authors.affiliation: State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School Sichuan University, China; Cancer Center, West China Hospital, Sichuan University, China.
authors.forename: Ma
authors.initials: M
authors.lastname: Xuelei
authors.affiliation: West China Medical School, West China Hospital, Sichuan University, China.
authors.forename: Huang
authors.initials: H
authors.lastname: Jingwen
authors.affiliation: State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School Sichuan University, China.
authors.forename: Du
authors.initials: D
authors.lastname: Wei
authors.affiliation: Cancer Center, West China Hospital, Sichuan University, China.
authors.forename: Zhuo
authors.initials: Z
authors.lastname: Hongyu
authors.affiliation: West China Medical School, West China Hospital, Sichuan University, China.
authors.forename: Zhang
authors.initials: Z
authors.lastname: Jing
authors.affiliation: West China Medical School, West China Hospital, Sichuan University, China.
authors.forename: Shi
authors.initials: S
authors.lastname: Changle
authors.affiliation: State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School Sichuan University, China; Cancer Center, West China Hospital, Sichuan University, China. Electronic address: liuleihx@gmail.com.
authors.forename: Liu
authors.initials: L
authors.lastname: Lei
mesh_terms: D015415:Biomarkers / Q000378:metabolism*; D002294:Carcinoma, Squamous Cell / Q000378:metabolism / Q000473:pathology*; D004268:DNA-Binding Proteins / Q000378:metabolism*; D004720:Endonucleases / Q000378:metabolism*; D006258:Head and Neck Neoplasms / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D004268:DNA-Binding Proteins; C071447:ERCC1 protein, human; D004720:Endonucleases
keywords: Chemoradiotherapy; Cisplatin; ERCC1; HNSCC; Meta-analysis; Prognosis; Radiotherapy; Treatment response